Pseudomonas aeruginosa is a ubiquitous Gram-negative opportunistic pathogen of compromised patients. Especially susceptible are individuals inflicted with severe burn wounds, surgery, eye complications, and cystic fibrosis. P. aeruginosa pathogenesis is facilitated by its ability to grow in hospital environments and its intrinsic resistant to antibiotics. P. aeruginosa produces a number of virulence determinants, which are either cell-surface components or secreted. The goal of this proposal is to define the role of exoenzyme S (ExoS) in P. aeruginosa pathogenesis. Recent studies have shown ExoS to be a bifunctional type-III secreted cytotoxin. Expression of the amino terminus of ExoS in eukaryotic cells stimulates actin reorganization, which involves small-molecular-weight GTPases of the Rho subfamily. Expression of the carboxyl terminus of ExoS, the ADP- ribosyltransferase domain, inhibits the activation of Ras by its guanine nucleotide exchange factor. Rho and Ras are molecular switches, which control numerous cellular processes, including wound healing, tissue regeneration, phagocytosis, and T cell activation. This proposal will address the molecular basis for the inhibition of signal transduction by ExoS, by determining the roles that ADP-ribosylation and cytoskeleton rearrangement play in the pathogenesis of P. aeruginosa. The hypothesis is that ExoS allows P. aeruginosa to establish an initial site of infection, through the inhibition of Ras- and Rho- mediated signal transduction pathways, which are essential for cell proliferation. Understanding the molecular properties of ExoS should provide insight into the development of vaccines and therapeutics to prevent the clinical manifestations of P. aeruginosa infections.
The specific aims of this proposal are to: define the biochemical and cellular properties of ExoS and ExoT, measure in vitro and in vivo ADP-ribosylation of eukaryotic proteins by ExoS, and determine the molecular basis for actin reorganization elicited by ExoS.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI030162-11
Application #
6510456
Study Section
Special Emphasis Panel (ZRG1-MBC-1 (03))
Program Officer
Taylor, Christopher E,
Project Start
1990-07-01
Project End
2005-06-30
Budget Start
2002-07-01
Budget End
2003-06-30
Support Year
11
Fiscal Year
2002
Total Cost
$299,000
Indirect Cost
Name
Medical College of Wisconsin
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
073134603
City
Milwaukee
State
WI
Country
United States
Zip Code
53226
Zuverink, Madison; Barbieri, Joseph T (2018) Protein Toxins That Utilize Gangliosides as Host Receptors. Prog Mol Biol Transl Sci 156:325-354
Zuverink, Madison; Barbieri, Joseph T (2017) Protein Structure Facilitates High-Resolution Immunological Mapping. Clin Vaccine Immunol 24:
Kroken, Abby R; Blum, Faith C; Zuverink, Madison et al. (2017) Entry of Botulinum Neurotoxin Subtypes A1 and A2 into Neurons. Infect Immun 85:
Chen, Chen; Barbieri, Joseph T (2017) When Escherichia coli doesn't fit the mold: A pertussis-like toxin with altered specificity. J Biol Chem 292:15159-15160
Chen, Sheng; Barbieri, Joseph T (2016) Solubility of the catalytic domains of Botulinum neurotoxin serotype E subtypes. Protein Expr Purif 118:18-24
Chen, Chen; Przedpelski, Amanda; Tepp, William H et al. (2015) Heat-Labile Enterotoxin IIa, a Platform To Deliver Heterologous Proteins into Neurons. MBio 6:e00734
Zuverink, Madison; Chen, Chen; Przedpelski, Amanda et al. (2015) A Heterologous Reporter Defines the Role of the Tetanus Toxin Interchain Disulfide in Light-Chain Translocation. Infect Immun 83:2714-24
Zuverink, Madison; Barbieri, Joseph T (2015) From GFP to ?-lactamase: advancing intact cell imaging for toxins and effectors. Pathog Dis 73:ftv097
Simon, Nathan C; Aktories, Klaus; Barbieri, Joseph T (2014) Novel bacterial ADP-ribosylating toxins: structure and function. Nat Rev Microbiol 12:599-611
Simon, Nathan C; Barbieri, Joseph T (2014) Exoenzyme S ADP-ribosylates Rab5 effector sites to uncouple intracellular trafficking. Infect Immun 82:21-8

Showing the most recent 10 out of 70 publications